×
Request Free Sample ×
ReportInfographic

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background
English
Chinese
French
Japanese
Korean
German
Spanish

Global Blood Coagulants Market Share

ID: MRFR/HC/6163-HCR
160 Pages
Kinjoll Dey
February 2026

Blood Coagulants Market Research Report Information by Type (Coagulation Factor (Recombinant Coagulation Factor & Plasma-Derived Coagulation Factor) & Others), & Indication (Hemophilia, Surgery, & Other Bleeding Disorders)—Forecast till 2035

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Global Blood Coagulants Market Infographic
Request Free Sample
Purchase Options
Compare License
Summary Table of Contents Segmentation Download PDF

Market Share

Global Blood Coagulants Market Share Analysis

The Blood Coagulants Market uses market share positioning tactics to compete and meet clotting disease medical demands. Companies differentiate by producing new blood coagulants with improved efficacy and safety. Companies can create enhanced clotting factors, anticoagulants, and hemostatic drugs by investing in R&D. With a reputation for sophisticated and dependable hemostasis, firms may charge premium pricing for their specialty blood coagulants and attract healthcare providers seeking cutting-edge treatments.

Another important Blood Coagulants Market approach is cost leadership. Companies aim to offer high-quality, affordable clotting solutions. This strategy works well in healthcare-cost-sensitive markets. Companies may deliver economical, dependable blood coagulants by optimizing production processes, simplifying supply networks, and using economies of scale. This technique tackles healthcare providers' financial restraints and helps them enter new markets where cost-effectiveness is crucial.

In the Blood Coagulants Market, firms adapt their coagulants to specific medicinal uses, patient groups, and clotting diseases. Coagulation therapy vary by disease, therefore customisation guarantees that each product fulfills the demands of the intended patient group. Companies can obtain a competitive edge by tailoring their blood coagulants to hematologists, healthcare facilities, and patients. Specialization in specialized therapeutic areas helps organizations become market leaders and generate confidence with their target audience.

Collaboration and collaborations affect Blood Coagulants Market share. Strategic partnerships with hematologists, medical institutes, and research groups let firms exchange resources, knowledge, and product development. Collaborations enable clinical studies, real-world validations, and scientific insights into coagulant design, improving blood coagulant efficacy and safety. Companies may learn about developing trends and guarantee their coagulants match healthcare professionals' and patients' demands by aligning with key opinion leaders.

Success in the Blood Coagulants Market requires constant innovation. Research and development, technical breakthroughs, and coagulant adaptations help companies gain market share. Adding prolonged half-lives, reversible anticoagulation effects, and tailored dosage to blood coagulants improves patient-specific clotting control. Continuous development keeps organizations ahead of the competition, giving healthcare practitioners cutting-edge technologies to better patient care and results."

Author
Kinjoll Dey
Senior Research Analyst

He is an extremely curious individual currently working in Healthcare and Medical Devices Domain. Kinjoll is comfortably versed in data centric research backed by healthcare educational background. He leverages extensive data mining and analytics tools such as Primary and Secondary Research, Statistical Analysis, Machine Learning, Data Modelling. His key role also involves Technical Sales Support, Client Interaction and Project management within the Healthcare team. Lastly, he showcases extensive affinity towards learning new skills and remain fascinated in implementing them.

Get In Touch

Leave a Comment

FAQs

What is the current valuation of the Blood Coagulants Market as of 2024?

<p>The Blood Coagulants Market was valued at 3.39 USD Billion in 2024.</p>

What is the projected market valuation for the Blood Coagulants Market in 2035?

<p>The market is projected to reach 7.033 USD Billion by 2035.</p>

What is the expected CAGR for the Blood Coagulants Market during the forecast period 2025 - 2035?

<p>The expected CAGR for the Blood Coagulants Market during 2025 - 2035 is 6.86%.</p>

Which companies are considered key players in the Blood Coagulants Market?

<p>Key players include Baxter International, Boehringer Ingelheim, Johnson & Johnson, Roche, CSL Behring, Amgen, Grifols, Octapharma, and Sobi.</p>

What are the main segments of the Blood Coagulants Market?

<p>The main segments include Coagulation Factor types, with notable categories being Recombinant and Plasma-Derived Coagulation Factors.</p>

How did the Coagulation Factor segment perform in terms of valuation?

The Coagulation Factor segment was valued at 2.5 USD Billion in 2024 and is expected to grow to 5.0 USD Billion by 2035.

What are the indications driving the Blood Coagulants Market?

Indications include Hemophilia, Surgery, and Other Bleeding Disorders, with Hemophilia valued at 1.5 USD Billion in 2024.

What is the projected growth for the Hemophilia indication by 2035?

The Hemophilia indication is projected to grow from 1.5 USD Billion in 2024 to 3.1 USD Billion by 2035.

How does the Plasma-Derived Coagulation Factor segment compare to the Recombinant Coagulation Factor segment?

In 2024, the Plasma-Derived Coagulation Factor was valued at 1.7 USD Billion, while the Recombinant Coagulation Factor was valued at 1.69 USD Billion.

What is the expected growth for the Surgery indication in the Blood Coagulants Market?

The Surgery indication is expected to grow from 1.2 USD Billion in 2024 to 2.5 USD Billion by 2035.

Market Summary

As per Market Research Future analysis, the Blood Coagulants Market Size was estimated at 3.39 USD Billion in 2024. The Blood Coagulants industry is projected to grow from 3.623 USD Billion in 2025 to 7.033 USD Billion by 2035, exhibiting a compound annual growth rate (CAGR) of 6.86% during the forecast period 2025 - 2035

Key Market Trends & Highlights

The Blood Coagulants Market is experiencing robust growth driven by technological advancements and increasing demand for personalized medicine.

  • Technological advancements in coagulant formulations are reshaping the market landscape. North America remains the largest market, while Asia-Pacific is emerging as the fastest-growing region. The coagulation factor segment holds the largest market share, whereas the plasma-derived coagulation factor segment is witnessing rapid growth. Key market drivers include the growing incidence of hemorrhagic disorders and the expansion of surgical procedures.

Market Size & Forecast

2024 Market Size 3.39 (USD Billion)
2035 Market Size 7.033 (USD Billion)
CAGR (2025 - 2035) 6.86%
Largest Regional Market Share in 2024 Americas

Major Players

Baxter International (US), Boehringer Ingelheim (DE), Johnson &amp; Johnson (US), Roche (CH), CSL Behring (AU), Amgen (US), Grifols (ES), Octapharma (CH), Sobi (SE)

Market Trends

The Blood Coagulants Market is currently experiencing a notable transformation, driven by advancements in medical technology and an increasing understanding of coagulation disorders. The demand for effective hemostatic agents is rising, as healthcare providers seek to enhance patient outcomes in surgical and trauma settings. Innovations in drug formulations and delivery methods are likely to play a crucial role in shaping the future landscape of this market. Furthermore, the growing prevalence of bleeding disorders and the aging population are contributing to the heightened need for reliable coagulants, suggesting a robust growth trajectory for the industry. In addition, regulatory bodies are becoming more involved in the approval processes for new coagulant therapies, which may influence market dynamics. The emphasis on safety and efficacy is paramount, as stakeholders aim to ensure that products meet stringent quality standards. As the Blood Coagulants Market evolves, collaboration between pharmaceutical companies and research institutions appears essential for fostering innovation and addressing unmet medical needs. Overall, the market is poised for expansion, with various factors indicating a promising future for blood coagulant products and therapies.

Technological Advancements in Coagulant Formulations

Recent innovations in drug formulations are enhancing the efficacy and safety profiles of blood coagulants. These advancements may lead to the development of more targeted therapies that address specific coagulation disorders, potentially improving patient outcomes.

Rising Demand for Personalized Medicine

The trend towards personalized medicine is influencing the Blood Coagulants Market, as healthcare providers increasingly seek tailored treatment options for patients. This shift may drive the development of coagulants that are customized based on individual patient profiles.

Increased Focus on Regulatory Compliance

Regulatory agencies are intensifying their scrutiny of blood coagulant products, emphasizing the need for rigorous testing and validation. This focus on compliance may lead to higher standards in product development, ultimately benefiting patient safety and treatment efficacy.

Global Blood Coagulants Market Market Drivers

Expansion of Surgical Procedures

The increasing number of surgical procedures worldwide is another significant driver for the Blood Coagulants Market. Surgical interventions, ranging from elective surgeries to complex operations, often require effective hemostatic agents to minimize bleeding risks. Data suggests that surgical procedures have been on the rise, with millions performed annually across various specialties. This trend underscores the necessity for reliable blood coagulants to ensure patient safety and optimal surgical outcomes. As surgical techniques evolve and become more sophisticated, the demand for advanced coagulant products is likely to grow. Consequently, the Blood Coagulants Market is expected to benefit from this surge in surgical activity, as healthcare providers prioritize effective hemostatic solutions.

Rising Awareness of Blood Disorders

The growing awareness of blood disorders among healthcare professionals and the general public is a notable driver for the Blood Coagulants Market. Educational initiatives and advocacy campaigns have contributed to increased recognition of conditions such as hemophilia and thrombosis. This heightened awareness is likely to lead to earlier diagnosis and treatment, thereby driving demand for blood coagulants. Furthermore, as patients become more informed about their health conditions, they may actively seek out effective treatment options. This trend is expected to foster a more robust market environment, as healthcare providers respond to the needs of informed patients. The Blood Coagulants Market is thus poised for growth as awareness continues to rise.

Growing Incidence of Hemorrhagic Disorders

The rising prevalence of hemorrhagic disorders, such as hemophilia and von Willebrand disease, is a critical driver for the Blood Coagulants Market. As the population ages, the incidence of these conditions appears to increase, necessitating effective treatment options. According to recent estimates, approximately 1 in 10,000 individuals are affected by hemophilia, leading to a heightened demand for coagulant therapies. This trend is likely to propel the market forward, as healthcare providers seek innovative solutions to manage these disorders. Furthermore, advancements in treatment modalities, including recombinant factor therapies, are expected to enhance patient outcomes, thereby stimulating market growth. The Blood Coagulants Market is thus positioned to expand in response to these evolving healthcare needs.

Increased Investment in Research and Development

Investment in research and development within the pharmaceutical sector is a pivotal driver for the Blood Coagulants Market. Companies are increasingly focusing on developing novel coagulant formulations that offer enhanced efficacy and safety profiles. This trend is evidenced by the growing number of clinical trials aimed at evaluating new coagulant therapies. For instance, recent data indicates that R&D spending in the pharmaceutical industry has reached unprecedented levels, with billions allocated to innovative drug development. Such investments are likely to yield breakthroughs in blood coagulation therapies, thereby expanding the market. The Blood Coagulants Market stands to gain from these advancements, as new products enter the market and address unmet medical needs.

Technological Innovations in Coagulation Testing

Technological innovations in coagulation testing are emerging as a significant driver for the Blood Coagulants Market. Advances in diagnostic technologies, such as point-of-care testing and automated laboratory systems, are enhancing the ability to assess coagulation status rapidly and accurately. This is particularly relevant in emergency settings, where timely intervention is crucial. The integration of these technologies into clinical practice is likely to facilitate better management of patients requiring coagulant therapies. As healthcare systems adopt these innovations, the demand for effective blood coagulants is expected to increase. The Blood Coagulants Market is thus benefiting from the synergy between diagnostic advancements and therapeutic solutions.

Market Segment Insights

By Type: Coagulation Factor (Largest) vs. Others (Fastest-Growing)

In the Blood Coagulants Market, the segment distribution reveals that Coagulation Factor holds a significant share, establishing itself as the largest segment due to its essential role in diagnosing and treating bleeding disorders. This segment's dominance is attributed to the widespread application of factor replacement therapies in hemophilia and other clotting disorders, ensuring its robustness in the market dynamics. On the contrary, the Others segment, which encompasses alternative blood coagulation products, is emerging rapidly, driven by innovations and adjunct therapies that complement traditional treatment methods.

Coagulation Factor: Dominant vs. Others: Emerging

The Coagulation Factor segment is characterized by its critical importance and extensive use in medical settings, particularly among hemophilia patients who rely on factor replacement therapy for effective treatment. Its established position is bolstered by continuous advancements in biopharmaceuticals, leading to improved product efficacy and patient outcomes. In juxtaposition, the Others segment captures a growing variety of new entrants and complementary products that provide innovative approaches to blood coagulation management, such as non-factor therapies. As healthcare providers explore diverse treatment modalities, the Others segment is poised for rapid expansion, attracting considerable interest from manufacturers and researchers alike.

By Coagulation Factor: Recombinant Coagulation Factor (Largest) vs. Plasma-Derived Coagulation Factor (Fastest-Growing)

In the Blood Coagulants Market, the Recombinant Coagulation Factor has established itself as the largest segment, capturing a significant share of the market. This segment's dominance can be attributed to its growing acceptance among healthcare providers due to safety and efficacy, particularly for patients with hemophilia. On the other hand, the Plasma-Derived Coagulation Factor is gaining traction, reflecting a steady increase in usage driven by the rising prevalence of bleeding disorders and an expanding patient population seeking treatment options.

Recombinant Coagulation Factor (Dominant) vs. Plasma-Derived Coagulation Factor (Emerging)

Recombinant Coagulation Factor remains the dominant player in the Blood Coagulants Market due to its synthetic production process that reduces the risk of disease transmission, making it a preferred choice for patients with hemophilia. Its innovation in formulation is characterized by longer half-lives and improved dosing regimens. Alternatively, Plasma-Derived Coagulation Factor is emerging as a critical segment, particularly in regions where cost-effective treatments are prioritized. It is derived from human plasma and, while it poses some risks such as viral contamination, the segment's focus on advancements in purification and testing technology is driving its growth. This continuous development is likely to bolster its position in the market for the foreseeable future.

By Indication: Hemophilia (Largest) vs. Surgery (Fastest-Growing)

In the Blood Coagulants Market, the indication segment is characterized by three primary categories: Hemophilia, Surgery, and Other Bleeding Disorders. Hemophilia holds the largest market share, significantly influencing the development and preference for coagulants in clinical settings. Surgery is emerging as a major player, with escalating demand as surgical procedures worldwide increase. Other bleeding disorders, while important, command a lesser portion of the overall market due to limited treatment options available compared to the more established categories.

Hemophilia (Dominant) vs. Surgery (Emerging)

The Hemophilia segment remains dominant in the Blood Coagulants Market, primarily due to its long-standing history and the high prevalence of hemophilia among populations. Treatments in this category are well-established and include a range of factor replacement therapies. The Surgery segment, however, is emerging rapidly, fueled by the rise in surgical procedures and the need for effective coagulation management during and post-surgery. This segment's growth is propelled by advancements in surgical techniques and an increasing emphasis on minimizing bleeding risks, making surgical coagulants critical for improving patient outcomes. Together, these segments define the market dynamics and present vast opportunities for innovation.

Get more detailed insights about Blood Coagulants Market Research Report - Global Forecast till 2035

Regional Insights

North America : Market Leader in Coagulants

North America is the largest market for blood coagulants, holding approximately 45% of the global market share. The region's growth is driven by increasing incidences of bleeding disorders, advancements in medical technology, and supportive regulatory frameworks. The demand for innovative therapies and the rising geriatric population further fuel market expansion. Regulatory bodies like the FDA play a crucial role in ensuring the safety and efficacy of these products, thereby enhancing market growth. The United States is the leading country in this region, with significant contributions from key players such as Baxter International and Johnson & Johnson. Canada also plays a vital role, with a growing focus on research and development in the healthcare sector. The competitive landscape is characterized by collaborations and mergers among major companies, ensuring a steady supply of advanced coagulant therapies to meet the rising demand.

Europe : Emerging Market Dynamics

Europe is the second-largest market for blood coagulants, accounting for approximately 30% of the global market share. The region is witnessing growth due to increasing awareness of bleeding disorders, advancements in healthcare infrastructure, and favorable reimbursement policies. The European Medicines Agency (EMA) plays a significant role in regulating blood coagulants, ensuring that innovative therapies are accessible to patients while maintaining high safety standards. Leading countries in this region include Germany, France, and the United Kingdom, which are home to several key players like Boehringer Ingelheim and Roche. The competitive landscape is marked by a strong presence of both established companies and emerging startups focusing on novel therapies. Collaborations between pharmaceutical companies and research institutions are also on the rise, enhancing the development of effective coagulant solutions.

Asia-Pacific : Rapidly Growing Market

Asia-Pacific is an emerging powerhouse in the blood coagulants market, holding approximately 20% of the global market share. The region's growth is driven by increasing healthcare expenditure, rising awareness of bleeding disorders, and a growing population. Countries like China and India are witnessing significant demand for blood coagulants due to their large patient populations and improving healthcare infrastructure. Regulatory bodies in these countries are also becoming more proactive in approving new therapies, further catalyzing market growth. China is the largest market in the region, followed by India and Japan. The competitive landscape is characterized by a mix of local and international players, including CSL Behring and Grifols. The presence of key players is bolstered by strategic partnerships and collaborations aimed at enhancing product offerings and expanding market reach. As the region continues to develop, the demand for innovative coagulant therapies is expected to rise significantly.

Middle East and Africa : Untapped Market Potential

The Middle East and Africa represent a resource-rich frontier for the blood coagulants market, holding approximately 5% of the global market share. The growth in this region is primarily driven by increasing healthcare investments, rising awareness of bleeding disorders, and improving access to healthcare services. Regulatory frameworks are gradually evolving, with governments focusing on enhancing healthcare infrastructure and ensuring the availability of essential medical products. Leading countries in this region include South Africa, Saudi Arabia, and the UAE, where there is a growing demand for blood coagulants. The competitive landscape is still developing, with both local and international players vying for market share. Companies are increasingly focusing on establishing distribution networks and partnerships to enhance their presence in this untapped market, paving the way for future growth in blood coagulants.

Key Players and Competitive Insights

The Blood Coagulants Market is currently characterized by a dynamic competitive landscape, driven by increasing demand for advanced therapeutic solutions and a growing prevalence of bleeding disorders. Key players such as Baxter International (US), Boehringer Ingelheim (DE), and CSL Behring (AU) are strategically positioned to leverage innovation and expand their market presence. Baxter International (US) focuses on enhancing its product portfolio through research and development, while Boehringer Ingelheim (DE) emphasizes strategic partnerships to bolster its market reach. CSL Behring (AU) is actively pursuing regional expansion, particularly in emerging markets, thereby shaping a competitive environment that is increasingly collaborative yet fiercely competitive.

The Blood Coagulants Market exhibits a moderately fragmented structure, with several players vying for market share. Key business tactics include localizing manufacturing to reduce costs and optimize supply chains, which is essential in maintaining competitive pricing. The collective influence of these major players fosters a competitive atmosphere where innovation and operational efficiency are paramount, allowing them to respond swiftly to market demands and regulatory changes.

In August 2025, Baxter International (US) announced the launch of a new line of recombinant clotting factors aimed at improving patient outcomes in hemophilia treatment. This strategic move not only enhances Baxter's product offerings but also positions the company as a leader in innovative therapies, potentially increasing its market share in a highly competitive segment. The introduction of these advanced therapies is likely to attract attention from healthcare providers seeking effective treatment options.

In September 2025, Boehringer Ingelheim (DE) entered into a collaboration with a leading biotechnology firm to develop next-generation blood coagulants utilizing AI-driven research methodologies. This partnership underscores Boehringer Ingelheim's commitment to integrating cutting-edge technology into its product development processes, which may lead to more effective and personalized treatment options. Such strategic alliances are indicative of a broader trend towards innovation in the market.

In July 2025, CSL Behring (AU) expanded its manufacturing capabilities in Asia, aiming to enhance its supply chain efficiency and meet the growing demand for blood coagulants in the region. This expansion not only reflects CSL Behring's proactive approach to market demands but also highlights the importance of regional manufacturing in ensuring timely product availability. The strategic focus on local production may provide a competitive edge in terms of responsiveness and cost-effectiveness.

As of October 2025, the Blood Coagulants Market is witnessing significant trends such as digitalization, sustainability, and the integration of artificial intelligence in product development. Strategic alliances among key players are increasingly shaping the competitive landscape, fostering innovation and collaboration. Looking ahead, competitive differentiation is likely to evolve from traditional price-based competition towards a focus on technological advancements, innovative solutions, and reliable supply chains, thereby redefining the parameters of success in this vital market.

Key Companies in the Global Blood Coagulants Market include

Industry Developments

Future Outlook

Global Blood Coagulants Market Future Outlook

The Blood Coagulants Market is projected to grow at a 6.86% CAGR from 2025 to 2035, driven by advancements in medical technology, increasing surgical procedures, and rising awareness of coagulation disorders.

New opportunities lie in:

  • <p>Development of personalized coagulant therapies for specific patient profiles. Expansion of telehealth services for remote monitoring of coagulation levels. Investment in AI-driven diagnostic tools for early detection of coagulation disorders.</p>

By 2035, the Blood Coagulants Market is expected to achieve substantial growth, reflecting evolving healthcare needs.

Market Segmentation

Global Blood Coagulants Market Type Outlook

  • Coagulation Factor
  • Others

Global Blood Coagulants Market Indication Outlook

  • Hemophilia
  • Surgery
  • Other Bleeding Disorders

Global Blood Coagulants Market Coagulation Factor Outlook

  • Recombinant Coagulation Factor
  • Plasma-Derived Coagulation Factor

Report Scope

MARKET SIZE 2024 3.39(USD Billion)
MARKET SIZE 2025 3.623(USD Billion)
MARKET SIZE 2035 7.033(USD Billion)
COMPOUND ANNUAL GROWTH RATE (CAGR) 6.86% (2025 - 2035)
REPORT COVERAGE Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
BASE YEAR 2024
Market Forecast Period 2025 - 2035
Historical Data 2019 - 2024
Market Forecast Units USD Billion
Key Companies Profiled Baxter International (US), Boehringer Ingelheim (DE), Johnson & Johnson (US), Roche (CH), CSL Behring (AU), Amgen (US), Grifols (ES), Octapharma (CH), Sobi (SE)
Segments Covered Type
Key Market Opportunities Advancements in biotechnology are enhancing the efficacy and safety of Blood Coagulants Market products.
Key Market Dynamics Rising demand for innovative blood coagulants drives competitive forces and regulatory adaptations in the healthcare sector.
Countries Covered North America, Europe, APAC, South America, MEA

FAQs

What is the current valuation of the Blood Coagulants Market as of 2024?

<p>The Blood Coagulants Market was valued at 3.39 USD Billion in 2024.</p>

What is the projected market valuation for the Blood Coagulants Market in 2035?

<p>The market is projected to reach 7.033 USD Billion by 2035.</p>

What is the expected CAGR for the Blood Coagulants Market during the forecast period 2025 - 2035?

<p>The expected CAGR for the Blood Coagulants Market during 2025 - 2035 is 6.86%.</p>

Which companies are considered key players in the Blood Coagulants Market?

<p>Key players include Baxter International, Boehringer Ingelheim, Johnson & Johnson, Roche, CSL Behring, Amgen, Grifols, Octapharma, and Sobi.</p>

What are the main segments of the Blood Coagulants Market?

<p>The main segments include Coagulation Factor types, with notable categories being Recombinant and Plasma-Derived Coagulation Factors.</p>

How did the Coagulation Factor segment perform in terms of valuation?

The Coagulation Factor segment was valued at 2.5 USD Billion in 2024 and is expected to grow to 5.0 USD Billion by 2035.

What are the indications driving the Blood Coagulants Market?

Indications include Hemophilia, Surgery, and Other Bleeding Disorders, with Hemophilia valued at 1.5 USD Billion in 2024.

What is the projected growth for the Hemophilia indication by 2035?

The Hemophilia indication is projected to grow from 1.5 USD Billion in 2024 to 3.1 USD Billion by 2035.

How does the Plasma-Derived Coagulation Factor segment compare to the Recombinant Coagulation Factor segment?

In 2024, the Plasma-Derived Coagulation Factor was valued at 1.7 USD Billion, while the Recombinant Coagulation Factor was valued at 1.69 USD Billion.

What is the expected growth for the Surgery indication in the Blood Coagulants Market?

The Surgery indication is expected to grow from 1.2 USD Billion in 2024 to 2.5 USD Billion by 2035.

  1. SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
    1. | 1.1 EXECUTIVE SUMMARY
    2. | | 1.1.1 Market Overview
    3. | | 1.1.2 Key Findings
    4. | | 1.1.3 Market Segmentation
    5. | | 1.1.4 Competitive Landscape
    6. | | 1.1.5 Challenges and Opportunities
    7. | | 1.1.6 Future Outlook
  2. SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
    1. | 2.1 MARKET INTRODUCTION
    2. | | 2.1.1 Definition
    3. | | 2.1.2 Scope of the study
    4. | | | 2.1.2.1 Research Objective
    5. | | | 2.1.2.2 Assumption
    6. | | | 2.1.2.3 Limitations
    7. | 2.2 RESEARCH METHODOLOGY
    8. | | 2.2.1 Overview
    9. | | 2.2.2 Data Mining
    10. | | 2.2.3 Secondary Research
    11. | | 2.2.4 Primary Research
    12. | | | 2.2.4.1 Primary Interviews and Information Gathering Process
    13. | | | 2.2.4.2 Breakdown of Primary Respondents
    14. | | 2.2.5 Forecasting Model
    15. | | 2.2.6 Market Size Estimation
    16. | | | 2.2.6.1 Bottom-Up Approach
    17. | | | 2.2.6.2 Top-Down Approach
    18. | | 2.2.7 Data Triangulation
    19. | | 2.2.8 Validation
  3. SECTION III: QUALITATIVE ANALYSIS
    1. | 3.1 MARKET DYNAMICS
    2. | | 3.1.1 Overview
    3. | | 3.1.2 Drivers
    4. | | 3.1.3 Restraints
    5. | | 3.1.4 Opportunities
    6. | 3.2 MARKET FACTOR ANALYSIS
    7. | | 3.2.1 Value chain Analysis
    8. | | 3.2.2 Porter's Five Forces Analysis
    9. | | | 3.2.2.1 Bargaining Power of Suppliers
    10. | | | 3.2.2.2 Bargaining Power of Buyers
    11. | | | 3.2.2.3 Threat of New Entrants
    12. | | | 3.2.2.4 Threat of Substitutes
    13. | | | 3.2.2.5 Intensity of Rivalry
    14. | | 3.2.3 COVID-19 Impact Analysis
    15. | | | 3.2.3.1 Market Impact Analysis
    16. | | | 3.2.3.2 Regional Impact
    17. | | | 3.2.3.3 Opportunity and Threat Analysis
  4. SECTION IV: QUANTITATIVE ANALYSIS
    1. | 4.1 Healthcare, BY Type (USD Billion)
    2. | | 4.1.1 Coagulation Factor
    3. | | 4.1.2 Others
    4. | 4.2 Healthcare, BY Coagulation Factor (USD Billion)
    5. | | 4.2.1 Recombinant Coagulation Factor
    6. | | 4.2.2 Plasma-Derived Coagulation Factor
    7. | 4.3 Healthcare, BY Indication (USD Billion)
    8. | | 4.3.1 Hemophilia
    9. | | 4.3.2 Surgery
    10. | | 4.3.3 Other Bleeding Disorders
    11. | 4.4 Healthcare, BY Region (USD Billion)
    12. | | 4.4.1 North America
    13. | | | 4.4.1.1 US
    14. | | | 4.4.1.2 Canada
    15. | | 4.4.2 Europe
    16. | | | 4.4.2.1 Germany
    17. | | | 4.4.2.2 UK
    18. | | | 4.4.2.3 France
    19. | | | 4.4.2.4 Russia
    20. | | | 4.4.2.5 Italy
    21. | | | 4.4.2.6 Spain
    22. | | | 4.4.2.7 Rest of Europe
    23. | | 4.4.3 APAC
    24. | | | 4.4.3.1 China
    25. | | | 4.4.3.2 India
    26. | | | 4.4.3.3 Japan
    27. | | | 4.4.3.4 South Korea
    28. | | | 4.4.3.5 Malaysia
    29. | | | 4.4.3.6 Thailand
    30. | | | 4.4.3.7 Indonesia
    31. | | | 4.4.3.8 Rest of APAC
    32. | | 4.4.4 South America
    33. | | | 4.4.4.1 Brazil
    34. | | | 4.4.4.2 Mexico
    35. | | | 4.4.4.3 Argentina
    36. | | | 4.4.4.4 Rest of South America
    37. | | 4.4.5 MEA
    38. | | | 4.4.5.1 GCC Countries
    39. | | | 4.4.5.2 South Africa
    40. | | | 4.4.5.3 Rest of MEA
  5. SECTION V: COMPETITIVE ANALYSIS
    1. | 5.1 Competitive Landscape
    2. | | 5.1.1 Overview
    3. | | 5.1.2 Competitive Analysis
    4. | | 5.1.3 Market share Analysis
    5. | | 5.1.4 Major Growth Strategy in the Healthcare
    6. | | 5.1.5 Competitive Benchmarking
    7. | | 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
    8. | | 5.1.7 Key developments and growth strategies
    9. | | | 5.1.7.1 New Product Launch/Service Deployment
    10. | | | 5.1.7.2 Merger & Acquisitions
    11. | | | 5.1.7.3 Joint Ventures
    12. | | 5.1.8 Major Players Financial Matrix
    13. | | | 5.1.8.1 Sales and Operating Income
    14. | | | 5.1.8.2 Major Players R&D Expenditure. 2023
    15. | 5.2 Company Profiles
    16. | | 5.2.1 Baxter International (US)
    17. | | | 5.2.1.1 Financial Overview
    18. | | | 5.2.1.2 Products Offered
    19. | | | 5.2.1.3 Key Developments
    20. | | | 5.2.1.4 SWOT Analysis
    21. | | | 5.2.1.5 Key Strategies
    22. | | 5.2.2 Boehringer Ingelheim (DE)
    23. | | | 5.2.2.1 Financial Overview
    24. | | | 5.2.2.2 Products Offered
    25. | | | 5.2.2.3 Key Developments
    26. | | | 5.2.2.4 SWOT Analysis
    27. | | | 5.2.2.5 Key Strategies
    28. | | 5.2.3 Johnson & Johnson (US)
    29. | | | 5.2.3.1 Financial Overview
    30. | | | 5.2.3.2 Products Offered
    31. | | | 5.2.3.3 Key Developments
    32. | | | 5.2.3.4 SWOT Analysis
    33. | | | 5.2.3.5 Key Strategies
    34. | | 5.2.4 Roche (CH)
    35. | | | 5.2.4.1 Financial Overview
    36. | | | 5.2.4.2 Products Offered
    37. | | | 5.2.4.3 Key Developments
    38. | | | 5.2.4.4 SWOT Analysis
    39. | | | 5.2.4.5 Key Strategies
    40. | | 5.2.5 CSL Behring (AU)
    41. | | | 5.2.5.1 Financial Overview
    42. | | | 5.2.5.2 Products Offered
    43. | | | 5.2.5.3 Key Developments
    44. | | | 5.2.5.4 SWOT Analysis
    45. | | | 5.2.5.5 Key Strategies
    46. | | 5.2.6 Amgen (US)
    47. | | | 5.2.6.1 Financial Overview
    48. | | | 5.2.6.2 Products Offered
    49. | | | 5.2.6.3 Key Developments
    50. | | | 5.2.6.4 SWOT Analysis
    51. | | | 5.2.6.5 Key Strategies
    52. | | 5.2.7 Grifols (ES)
    53. | | | 5.2.7.1 Financial Overview
    54. | | | 5.2.7.2 Products Offered
    55. | | | 5.2.7.3 Key Developments
    56. | | | 5.2.7.4 SWOT Analysis
    57. | | | 5.2.7.5 Key Strategies
    58. | | 5.2.8 Octapharma (CH)
    59. | | | 5.2.8.1 Financial Overview
    60. | | | 5.2.8.2 Products Offered
    61. | | | 5.2.8.3 Key Developments
    62. | | | 5.2.8.4 SWOT Analysis
    63. | | | 5.2.8.5 Key Strategies
    64. | | 5.2.9 Sobi (SE)
    65. | | | 5.2.9.1 Financial Overview
    66. | | | 5.2.9.2 Products Offered
    67. | | | 5.2.9.3 Key Developments
    68. | | | 5.2.9.4 SWOT Analysis
    69. | | | 5.2.9.5 Key Strategies
    70. | 5.3 Appendix
    71. | | 5.3.1 References
    72. | | 5.3.2 Related Reports
  6. LIST OF FIGURES
    1. | 6.1 MARKET SYNOPSIS
    2. | 6.2 NORTH AMERICA MARKET ANALYSIS
    3. | 6.3 US MARKET ANALYSIS BY TYPE
    4. | 6.4 US MARKET ANALYSIS BY COAGULATION FACTOR
    5. | 6.5 US MARKET ANALYSIS BY INDICATION
    6. | 6.6 CANADA MARKET ANALYSIS BY TYPE
    7. | 6.7 CANADA MARKET ANALYSIS BY COAGULATION FACTOR
    8. | 6.8 CANADA MARKET ANALYSIS BY INDICATION
    9. | 6.9 EUROPE MARKET ANALYSIS
    10. | 6.10 GERMANY MARKET ANALYSIS BY TYPE
    11. | 6.11 GERMANY MARKET ANALYSIS BY COAGULATION FACTOR
    12. | 6.12 GERMANY MARKET ANALYSIS BY INDICATION
    13. | 6.13 UK MARKET ANALYSIS BY TYPE
    14. | 6.14 UK MARKET ANALYSIS BY COAGULATION FACTOR
    15. | 6.15 UK MARKET ANALYSIS BY INDICATION
    16. | 6.16 FRANCE MARKET ANALYSIS BY TYPE
    17. | 6.17 FRANCE MARKET ANALYSIS BY COAGULATION FACTOR
    18. | 6.18 FRANCE MARKET ANALYSIS BY INDICATION
    19. | 6.19 RUSSIA MARKET ANALYSIS BY TYPE
    20. | 6.20 RUSSIA MARKET ANALYSIS BY COAGULATION FACTOR
    21. | 6.21 RUSSIA MARKET ANALYSIS BY INDICATION
    22. | 6.22 ITALY MARKET ANALYSIS BY TYPE
    23. | 6.23 ITALY MARKET ANALYSIS BY COAGULATION FACTOR
    24. | 6.24 ITALY MARKET ANALYSIS BY INDICATION
    25. | 6.25 SPAIN MARKET ANALYSIS BY TYPE
    26. | 6.26 SPAIN MARKET ANALYSIS BY COAGULATION FACTOR
    27. | 6.27 SPAIN MARKET ANALYSIS BY INDICATION
    28. | 6.28 REST OF EUROPE MARKET ANALYSIS BY TYPE
    29. | 6.29 REST OF EUROPE MARKET ANALYSIS BY COAGULATION FACTOR
    30. | 6.30 REST OF EUROPE MARKET ANALYSIS BY INDICATION
    31. | 6.31 APAC MARKET ANALYSIS
    32. | 6.32 CHINA MARKET ANALYSIS BY TYPE
    33. | 6.33 CHINA MARKET ANALYSIS BY COAGULATION FACTOR
    34. | 6.34 CHINA MARKET ANALYSIS BY INDICATION
    35. | 6.35 INDIA MARKET ANALYSIS BY TYPE
    36. | 6.36 INDIA MARKET ANALYSIS BY COAGULATION FACTOR
    37. | 6.37 INDIA MARKET ANALYSIS BY INDICATION
    38. | 6.38 JAPAN MARKET ANALYSIS BY TYPE
    39. | 6.39 JAPAN MARKET ANALYSIS BY COAGULATION FACTOR
    40. | 6.40 JAPAN MARKET ANALYSIS BY INDICATION
    41. | 6.41 SOUTH KOREA MARKET ANALYSIS BY TYPE
    42. | 6.42 SOUTH KOREA MARKET ANALYSIS BY COAGULATION FACTOR
    43. | 6.43 SOUTH KOREA MARKET ANALYSIS BY INDICATION
    44. | 6.44 MALAYSIA MARKET ANALYSIS BY TYPE
    45. | 6.45 MALAYSIA MARKET ANALYSIS BY COAGULATION FACTOR
    46. | 6.46 MALAYSIA MARKET ANALYSIS BY INDICATION
    47. | 6.47 THAILAND MARKET ANALYSIS BY TYPE
    48. | 6.48 THAILAND MARKET ANALYSIS BY COAGULATION FACTOR
    49. | 6.49 THAILAND MARKET ANALYSIS BY INDICATION
    50. | 6.50 INDONESIA MARKET ANALYSIS BY TYPE
    51. | 6.51 INDONESIA MARKET ANALYSIS BY COAGULATION FACTOR
    52. | 6.52 INDONESIA MARKET ANALYSIS BY INDICATION
    53. | 6.53 REST OF APAC MARKET ANALYSIS BY TYPE
    54. | 6.54 REST OF APAC MARKET ANALYSIS BY COAGULATION FACTOR
    55. | 6.55 REST OF APAC MARKET ANALYSIS BY INDICATION
    56. | 6.56 SOUTH AMERICA MARKET ANALYSIS
    57. | 6.57 BRAZIL MARKET ANALYSIS BY TYPE
    58. | 6.58 BRAZIL MARKET ANALYSIS BY COAGULATION FACTOR
    59. | 6.59 BRAZIL MARKET ANALYSIS BY INDICATION
    60. | 6.60 MEXICO MARKET ANALYSIS BY TYPE
    61. | 6.61 MEXICO MARKET ANALYSIS BY COAGULATION FACTOR
    62. | 6.62 MEXICO MARKET ANALYSIS BY INDICATION
    63. | 6.63 ARGENTINA MARKET ANALYSIS BY TYPE
    64. | 6.64 ARGENTINA MARKET ANALYSIS BY COAGULATION FACTOR
    65. | 6.65 ARGENTINA MARKET ANALYSIS BY INDICATION
    66. | 6.66 REST OF SOUTH AMERICA MARKET ANALYSIS BY TYPE
    67. | 6.67 REST OF SOUTH AMERICA MARKET ANALYSIS BY COAGULATION FACTOR
    68. | 6.68 REST OF SOUTH AMERICA MARKET ANALYSIS BY INDICATION
    69. | 6.69 MEA MARKET ANALYSIS
    70. | 6.70 GCC COUNTRIES MARKET ANALYSIS BY TYPE
    71. | 6.71 GCC COUNTRIES MARKET ANALYSIS BY COAGULATION FACTOR
    72. | 6.72 GCC COUNTRIES MARKET ANALYSIS BY INDICATION
    73. | 6.73 SOUTH AFRICA MARKET ANALYSIS BY TYPE
    74. | 6.74 SOUTH AFRICA MARKET ANALYSIS BY COAGULATION FACTOR
    75. | 6.75 SOUTH AFRICA MARKET ANALYSIS BY INDICATION
    76. | 6.76 REST OF MEA MARKET ANALYSIS BY TYPE
    77. | 6.77 REST OF MEA MARKET ANALYSIS BY COAGULATION FACTOR
    78. | 6.78 REST OF MEA MARKET ANALYSIS BY INDICATION
    79. | 6.79 KEY BUYING CRITERIA OF HEALTHCARE
    80. | 6.80 RESEARCH PROCESS OF MRFR
    81. | 6.81 DRO ANALYSIS OF HEALTHCARE
    82. | 6.82 DRIVERS IMPACT ANALYSIS: HEALTHCARE
    83. | 6.83 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
    84. | 6.84 SUPPLY / VALUE CHAIN: HEALTHCARE
    85. | 6.85 HEALTHCARE, BY TYPE, 2024 (% SHARE)
    86. | 6.86 HEALTHCARE, BY TYPE, 2024 TO 2035 (USD Billion)
    87. | 6.87 HEALTHCARE, BY COAGULATION FACTOR, 2024 (% SHARE)
    88. | 6.88 HEALTHCARE, BY COAGULATION FACTOR, 2024 TO 2035 (USD Billion)
    89. | 6.89 HEALTHCARE, BY INDICATION, 2024 (% SHARE)
    90. | 6.90 HEALTHCARE, BY INDICATION, 2024 TO 2035 (USD Billion)
    91. | 6.91 BENCHMARKING OF MAJOR COMPETITORS
  7. LIST OF TABLES
    1. | 7.1 LIST OF ASSUMPTIONS
    2. | | 7.1.1
    3. | 7.2 North America MARKET SIZE ESTIMATES; FORECAST
    4. | | 7.2.1 BY TYPE, 2025-2035 (USD Billion)
    5. | | 7.2.2 BY COAGULATION FACTOR, 2025-2035 (USD Billion)
    6. | | 7.2.3 BY INDICATION, 2025-2035 (USD Billion)
    7. | 7.3 US MARKET SIZE ESTIMATES; FORECAST
    8. | | 7.3.1 BY TYPE, 2025-2035 (USD Billion)
    9. | | 7.3.2 BY COAGULATION FACTOR, 2025-2035 (USD Billion)
    10. | | 7.3.3 BY INDICATION, 2025-2035 (USD Billion)
    11. | 7.4 Canada MARKET SIZE ESTIMATES; FORECAST
    12. | | 7.4.1 BY TYPE, 2025-2035 (USD Billion)
    13. | | 7.4.2 BY COAGULATION FACTOR, 2025-2035 (USD Billion)
    14. | | 7.4.3 BY INDICATION, 2025-2035 (USD Billion)
    15. | 7.5 Europe MARKET SIZE ESTIMATES; FORECAST
    16. | | 7.5.1 BY TYPE, 2025-2035 (USD Billion)
    17. | | 7.5.2 BY COAGULATION FACTOR, 2025-2035 (USD Billion)
    18. | | 7.5.3 BY INDICATION, 2025-2035 (USD Billion)
    19. | 7.6 Germany MARKET SIZE ESTIMATES; FORECAST
    20. | | 7.6.1 BY TYPE, 2025-2035 (USD Billion)
    21. | | 7.6.2 BY COAGULATION FACTOR, 2025-2035 (USD Billion)
    22. | | 7.6.3 BY INDICATION, 2025-2035 (USD Billion)
    23. | 7.7 UK MARKET SIZE ESTIMATES; FORECAST
    24. | | 7.7.1 BY TYPE, 2025-2035 (USD Billion)
    25. | | 7.7.2 BY COAGULATION FACTOR, 2025-2035 (USD Billion)
    26. | | 7.7.3 BY INDICATION, 2025-2035 (USD Billion)
    27. | 7.8 France MARKET SIZE ESTIMATES; FORECAST
    28. | | 7.8.1 BY TYPE, 2025-2035 (USD Billion)
    29. | | 7.8.2 BY COAGULATION FACTOR, 2025-2035 (USD Billion)
    30. | | 7.8.3 BY INDICATION, 2025-2035 (USD Billion)
    31. | 7.9 Russia MARKET SIZE ESTIMATES; FORECAST
    32. | | 7.9.1 BY TYPE, 2025-2035 (USD Billion)
    33. | | 7.9.2 BY COAGULATION FACTOR, 2025-2035 (USD Billion)
    34. | | 7.9.3 BY INDICATION, 2025-2035 (USD Billion)
    35. | 7.10 Italy MARKET SIZE ESTIMATES; FORECAST
    36. | | 7.10.1 BY TYPE, 2025-2035 (USD Billion)
    37. | | 7.10.2 BY COAGULATION FACTOR, 2025-2035 (USD Billion)
    38. | | 7.10.3 BY INDICATION, 2025-2035 (USD Billion)
    39. | 7.11 Spain MARKET SIZE ESTIMATES; FORECAST
    40. | | 7.11.1 BY TYPE, 2025-2035 (USD Billion)
    41. | | 7.11.2 BY COAGULATION FACTOR, 2025-2035 (USD Billion)
    42. | | 7.11.3 BY INDICATION, 2025-2035 (USD Billion)
    43. | 7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST
    44. | | 7.12.1 BY TYPE, 2025-2035 (USD Billion)
    45. | | 7.12.2 BY COAGULATION FACTOR, 2025-2035 (USD Billion)
    46. | | 7.12.3 BY INDICATION, 2025-2035 (USD Billion)
    47. | 7.13 APAC MARKET SIZE ESTIMATES; FORECAST
    48. | | 7.13.1 BY TYPE, 2025-2035 (USD Billion)
    49. | | 7.13.2 BY COAGULATION FACTOR, 2025-2035 (USD Billion)
    50. | | 7.13.3 BY INDICATION, 2025-2035 (USD Billion)
    51. | 7.14 China MARKET SIZE ESTIMATES; FORECAST
    52. | | 7.14.1 BY TYPE, 2025-2035 (USD Billion)
    53. | | 7.14.2 BY COAGULATION FACTOR, 2025-2035 (USD Billion)
    54. | | 7.14.3 BY INDICATION, 2025-2035 (USD Billion)
    55. | 7.15 India MARKET SIZE ESTIMATES; FORECAST
    56. | | 7.15.1 BY TYPE, 2025-2035 (USD Billion)
    57. | | 7.15.2 BY COAGULATION FACTOR, 2025-2035 (USD Billion)
    58. | | 7.15.3 BY INDICATION, 2025-2035 (USD Billion)
    59. | 7.16 Japan MARKET SIZE ESTIMATES; FORECAST
    60. | | 7.16.1 BY TYPE, 2025-2035 (USD Billion)
    61. | | 7.16.2 BY COAGULATION FACTOR, 2025-2035 (USD Billion)
    62. | | 7.16.3 BY INDICATION, 2025-2035 (USD Billion)
    63. | 7.17 South Korea MARKET SIZE ESTIMATES; FORECAST
    64. | | 7.17.1 BY TYPE, 2025-2035 (USD Billion)
    65. | | 7.17.2 BY COAGULATION FACTOR, 2025-2035 (USD Billion)
    66. | | 7.17.3 BY INDICATION, 2025-2035 (USD Billion)
    67. | 7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST
    68. | | 7.18.1 BY TYPE, 2025-2035 (USD Billion)
    69. | | 7.18.2 BY COAGULATION FACTOR, 2025-2035 (USD Billion)
    70. | | 7.18.3 BY INDICATION, 2025-2035 (USD Billion)
    71. | 7.19 Thailand MARKET SIZE ESTIMATES; FORECAST
    72. | | 7.19.1 BY TYPE, 2025-2035 (USD Billion)
    73. | | 7.19.2 BY COAGULATION FACTOR, 2025-2035 (USD Billion)
    74. | | 7.19.3 BY INDICATION, 2025-2035 (USD Billion)
    75. | 7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST
    76. | | 7.20.1 BY TYPE, 2025-2035 (USD Billion)
    77. | | 7.20.2 BY COAGULATION FACTOR, 2025-2035 (USD Billion)
    78. | | 7.20.3 BY INDICATION, 2025-2035 (USD Billion)
    79. | 7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST
    80. | | 7.21.1 BY TYPE, 2025-2035 (USD Billion)
    81. | | 7.21.2 BY COAGULATION FACTOR, 2025-2035 (USD Billion)
    82. | | 7.21.3 BY INDICATION, 2025-2035 (USD Billion)
    83. | 7.22 South America MARKET SIZE ESTIMATES; FORECAST
    84. | | 7.22.1 BY TYPE, 2025-2035 (USD Billion)
    85. | | 7.22.2 BY COAGULATION FACTOR, 2025-2035 (USD Billion)
    86. | | 7.22.3 BY INDICATION, 2025-2035 (USD Billion)
    87. | 7.23 Brazil MARKET SIZE ESTIMATES; FORECAST
    88. | | 7.23.1 BY TYPE, 2025-2035 (USD Billion)
    89. | | 7.23.2 BY COAGULATION FACTOR, 2025-2035 (USD Billion)
    90. | | 7.23.3 BY INDICATION, 2025-2035 (USD Billion)
    91. | 7.24 Mexico MARKET SIZE ESTIMATES; FORECAST
    92. | | 7.24.1 BY TYPE, 2025-2035 (USD Billion)
    93. | | 7.24.2 BY COAGULATION FACTOR, 2025-2035 (USD Billion)
    94. | | 7.24.3 BY INDICATION, 2025-2035 (USD Billion)
    95. | 7.25 Argentina MARKET SIZE ESTIMATES; FORECAST
    96. | | 7.25.1 BY TYPE, 2025-2035 (USD Billion)
    97. | | 7.25.2 BY COAGULATION FACTOR, 2025-2035 (USD Billion)
    98. | | 7.25.3 BY INDICATION, 2025-2035 (USD Billion)
    99. | 7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST
    100. | | 7.26.1 BY TYPE, 2025-2035 (USD Billion)
    101. | | 7.26.2 BY COAGULATION FACTOR, 2025-2035 (USD Billion)
    102. | | 7.26.3 BY INDICATION, 2025-2035 (USD Billion)
    103. | 7.27 MEA MARKET SIZE ESTIMATES; FORECAST
    104. | | 7.27.1 BY TYPE, 2025-2035 (USD Billion)
    105. | | 7.27.2 BY COAGULATION FACTOR, 2025-2035 (USD Billion)
    106. | | 7.27.3 BY INDICATION, 2025-2035 (USD Billion)
    107. | 7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST
    108. | | 7.28.1 BY TYPE, 2025-2035 (USD Billion)
    109. | | 7.28.2 BY COAGULATION FACTOR, 2025-2035 (USD Billion)
    110. | | 7.28.3 BY INDICATION, 2025-2035 (USD Billion)
    111. | 7.29 South Africa MARKET SIZE ESTIMATES; FORECAST
    112. | | 7.29.1 BY TYPE, 2025-2035 (USD Billion)
    113. | | 7.29.2 BY COAGULATION FACTOR, 2025-2035 (USD Billion)
    114. | | 7.29.3 BY INDICATION, 2025-2035 (USD Billion)
    115. | 7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST
    116. | | 7.30.1 BY TYPE, 2025-2035 (USD Billion)
    117. | | 7.30.2 BY COAGULATION FACTOR, 2025-2035 (USD Billion)
    118. | | 7.30.3 BY INDICATION, 2025-2035 (USD Billion)
    119. | 7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
    120. | | 7.31.1
    121. | 7.32 ACQUISITION/PARTNERSHIP
    122. | | 7.32.1

Healthcare Market Segmentation

Healthcare By Type (USD Billion, 2025-2035)

  • Coagulation Factor
  • Others

Healthcare By Coagulation Factor (USD Billion, 2025-2035)

  • Recombinant Coagulation Factor
  • Plasma-Derived Coagulation Factor

Healthcare By Indication (USD Billion, 2025-2035)

  • Hemophilia
  • Surgery
  • Other Bleeding Disorders
Infographic

Free Sample Request

Kindly complete the form below to receive a free sample of this Report

Get Free Sample

Related Reports

Regional Reports
Country Reports

Customer Strories

Customer Stories
Case Study Cover Image
Case Study
Aerospace & Defense
Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization ✓ ✓ ✓
Direct Access to Analyst ✓ ✓ ✓
Deliverable Format ✓ ✓ ✓
Platform Access ✗ ✗ ✓
Discount on Next Purchase 10% 15% 15%
Printable Versions ✗ ✗ ✓